Castle Biosciences, Inc. (CSTL) Financial Analysis & Valuation | Quarter Chart
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed wi... more
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and ... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $1.01B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Medical - Diagnostics & Research |
| Country | US | CEO | Derek J. Maetzold |
| IPO Date | 2019-07-25 | CAGR | 49.56% |
| Employees | 1,002 | Website | castlebiosciences.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
CSTL chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $864.25M | P/E | -50.29 | Forward P/E | -36.34 | PEG | — |
| P/S | 53646.22 | P/B | 40755.19 | P/CF | 449543.21 | P/FCF | 928470.93 |
| Sales | $357.28M | Sales 1Y | 3.18% | Sales 3Y | 113.27% | Sales 5Y | 357.54% |
| EPS | $-0.66 | EPS 1Y | 86.14% | EPS 3Y | -80.4% | EPS 5Y | -32.99% |
| Sales QoQ | 23.74% | EPS QoQ | -85.71% | Sales QoQ Avg | 5.26% | EPS QoQ Avg | 170.35% |
| Gross Margin | 54.13% | Operating Margin | -8.13% | Profit Margin | -5.43% | ROCE | -5.75% |
| ROA | -3% | ROE | -4% | Altman Z Score | 6.98 | Piotroski Score | 2 |
| Current Ratio | 6.04 | Quick Ratio | 5.85 | Cash Ratio | 1.1 | Op. CF Ratio | 0.27 |
| Debt/Equity | 0.08 | Debt/Assets | 0.07 | Lt Debt/Equity | 0.07 | Lt Debt/Cap. | 0.06 |
| Intrst Cov. | 2639.82 | Inventory Turnover | 5.7 | Asset Turnover | 0.64 | Receivables Turnover | 7.39 |
| Enterprise Value | $864.25M | P/E Ratio | -50.29 |
| Forward P/E | -36.34 | PEG Ratio | — |
| P/S Ratio | 53646.22 | P/B Ratio | 40755.19 |
| P/CF Ratio | 449543.21 | P/FCF Ratio | 928470.93 |
| EPS | $-0.66 | EPS Growth 1Y | 86.14% |
| EPS Growth 3Y | -80.4% | EPS Growth 5Y | -32.99% |
| Revenue Growth 1Y | 3.18% | Gross Margin | 54.13% |
| Operating Margin | -8.13% | Profit Margin | -5.43% |
| ROE | -4% | ROA | -3% |
| ROCE | -5.75% | Current Ratio | 6.04 |
| Quick Ratio | 5.85 | Cash Ratio | 1.1 |
| Debt/Equity | 0.08 | Interest Coverage | 2639.82 |
| Altman Z Score | 6.98 | Piotroski Score | 2 |
Castle Biosciences, Inc. (CSTL) valuation & financials
Castle Biosciences, Inc. (CSTL) has a market capitalization of $1.01B and trades at a price-to-earnings ratio of -50.3. It operates in the Healthcare sector (Medical - Diagnostics & Research).
Castle Biosciences, Inc.'s revenue grew +3.2% over the last year.
Castle Biosciences, Inc.'s next earnings report is scheduled for November 5, 2026 after market close (provider scheduled date); analysts estimate EPS of $-0.35. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)